Krystal Biotech (KRYS) Long-Term Investments (2019 - 2026)

Krystal Biotech (KRYS) has 7 years of Long-Term Investments data on file, last reported at $193.5 million in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Investments rose 30.32% year-over-year to $193.5 million; the trailing twelve-month figure through Mar 2026 stood at $193.5 million (up 30.32% YoY), and the FY2025 full-year result was $128.1 million, down 15.81% from the prior year.
• Long-Term Investments climbed to $193.5 million in Q1 2026, from $128.1 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $193.5 million in Q1 2026 to a low of $4.6 million in Q4 2022.
• A 5-year average of $79.3 million and a median of $69.3 million in 2024 frame the typical range for Long-Term Investments.
• Across the five-year window, Long-Term Investments slumped 92.82% in 2022 and soared 1537.67% in 2024, its largest moves.
• Tracing KRYS's Long-Term Investments over 5 years: stood at $4.6 million in 2022, then surged by 1240.71% to $62.0 million in 2023, then soared by 145.53% to $152.1 million in 2024, then retreated by 15.81% to $128.1 million in 2025, then surged by 51.08% to $193.5 million in 2026.
• Business Quant data shows KRYS's Long-Term Investments at $193.5 million in Q1 2026, $128.1 million in Q4 2025, and $133.1 million in Q3 2025.